Maintenance treatment with infliximab for ulcerative ileitis after intestinal transplantation: A case report

作     者：Takumi Fujimura Yohei Yamada Tomoshige Umeyama Yumi Kudo Hiroki Kanamori Teizaburo Mori Takahiro Shimizu Mototoshi Kato Miho Kawaida Naoki Hosoe Yasushi Hasegawa Kentaro Matsubara Naoki Shimojima Masahiro Shinoda Hideaki Obara Makoto Naganuma Yuko Kitagawa Ken Hoshino Tatsuo Kuroda 

作者机构：Department of Pediatric SurgeryNational Saitama HospitalWako ShiSaitama 351-0102Japan Department of Pediatric SurgeryKeio University School of MedicineTokyo 160-8582Japan Department of PathologyKeio University School of MedicineTokyo 160-8582Japan Center for Diagnostic and Therapeutic EndoscopyKeio University School ofMedicineTokyo 160-8582Japan Department of SurgeryKeio University School of MedicineTokyo 160-8582Japan Digestive Diseases CenterInternational University of Health and WelfareMita HospitalTokyo 108-8329Japan Department of Gastroenterology and HepatologyKeio University School of MedicineTokyo 160-8582Japan 

出 版 物：《World Journal of Clinical Cases》 (世界临床病例杂志)

年 卷 期：2021年第9卷第19期

页      面：5270-5279页

核心收录：

学科分类：1002[医学-临床医学] 100202[医学-儿科学] 10[医学] 

基　　金：Supported by JSPS KAKENHI No. JP18K16286  and No. JP18K08600 

主　　题：Intestinal transplantation Chronic ulcer Infliximab Crohn’s disease Tumor necrosis factor alpha Case report 

摘      要：BACKGROUND Evidence has been published on the successful applications of the anti-tumor necrosis factor alpha antibody infliximab,such as induction therapy,salvage treatment for acute cellular rejection,and treatment for chronic ulcerative inflammation,in intestinal transplant ***,the optimal protocol for the effective use of infliximab remains largely undetermined due to scarcity of available clinical *** report a continuative application of infliximab as maintenance therapy for recurrent chronic ulcerative ileitis in a recipient of isolated intestinal transplantation(ITx).CASE SUMMARY The patient was a 11-year-old boy with intestinal motility disorder classified as a hypogenic type of intestinal *** patient underwent living-donor related intestinal *** immunosuppression regimen consisted of daclizumab,tacrolimus,and *** he did not show rejection while on tacrolimus monotherapy,routine screening endoscopy showed several ulcerative lesions in the distal end of the graft 2 years after the intestinal *** work up to evaluate the progression of anemia revealed stenosis with ulcerative inflammatory changes and multiple longitudinal ulcers in the *** the endoscopic findings suggested ulcerative lesions in Crohn’s disease,infliximab treatment was *** with infliximab and a small dose of oral prednisolone afforded successful withdrawal of total parenteral nutrition and maintenance of a well-functioning graft without infectious complications for 5 years since the administration of the first dose of *** Infliximab is effective as maintenance therapy for recurrent chronic ulcerative ileitis in an isolated ITx patient.